MapLight Therapeutics pauses early‑stage programs to focus on lead schizophrenia and Alzheimer’s psychosis candidate

MapLight Therapeutics announced it is pausing its preclinical and discovery activities. The company said it will redirect resources toward advancing its lead candidate, ML-007C-MA, which is being developed for schizophrenia and Alzheimer’s disease‑related psychosis.

The pause affects all early‑stage projects that were not yet in clinical testing. By concentrating on a single program, MapLight hopes to accelerate development timelines and optimize its funding.

In a separate note, ADC Therapeutics is evaluating its options for the antibody‑drug conjugate Zynlonta. The company has not disclosed any specific actions, but the consideration reflects ongoing strategic reviews within the sector.

Both companies are adjusting their pipelines in response to internal priorities and market conditions, signaling a shift in focus toward later‑stage assets.